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ABSTRACT 
Rotaviral gastroenteritis is associated with high rate of infant mortality and morbidity. 
Antirotaviral activity has been associated with some glycoproteins, such as immunoglobulins 
A (IgA), lactoferrin (LF), mucins and lactadherin of human milk. Although holder 
pasteurization (HoP, 63 ºC for 30 min) is the treatment currently applied to human milk, it 
might may lead to a decrease of its bioactive properties. The antirotaviral capacity of human 
milk appears showed to be mainly associated with the whey fraction, focusing on IgA and LF, 
with neutralizing values of 100, 100 and 62%, at 1 mg protein/mL, respectively. HoP reduced 
the antirotaviral activity of human whey, IgA and LF, 30, 98 and 60%, respectively. 
Interestingly, both pasteurization (HTST) and HHP treatments were less harmful. Thus, 
Hhigh Ttemperature-Sshort Ttime (HTST) pasteurization at 75 ºC for 20 s did not affect the 
antirotaviral activity of samples, while the highest HHP treatment at 600 MPa for 15 min only 
reduced the activity of human whey, IgA and LF, 9, 40 and 10%, respectively.  
 
Keywords: Human milk / Antirotaviral activity / HoP / HTST / HHP 
 
Abbreviations: α-LA, α-lactalbumin; HoP, Holder pasteurization; HTST, high 
temperature-short time; HHP, High hydrostatic pressure; Igs, Immunoglobulins; IgA, 
Immunoglobulins A; LDH, Lactadherin; LF, Lactoferrin; Lyz, Lysozyme; MEM, Minimum 
essential medium; MFGM, Milk fat globule membrane; MUCs, Mucins; PBS, Phosphate-
buffered saline; rhLF, Recombinant human lactoferrin; rhLyz, Recombinant human lysozyme; 
SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
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1. Introduction  
Rotaviruses are the main cause of severe diarrheal disease in infants and young children, 
and the second cause of death in children less than 5-years-old (Marcotte & Hammarström, 
2016). The morbidity and mortality caused by viral gastroenteritis represent a major public 
health concern, affecting mainly the poorest countries (Das, Salam, & Bhutta, 2014).  
It has been demonstrated that the entry of rotaviruses into intestinal epithelial cells is a 
multistep process involving the virus outermost layer proteins of the virus, VP7 and VP4, and 
several cell surface molecules, with different requirements depending on the rotavirus strain 
(Arias, Silva-Ayala, Isa, Díaz-Salinas, & López, 2016). The virus replicates in the enterocytes 
of the small intestine, causing extensive damage to the microvilli and resulting in 
malabsorption and loss of fluids and electrolytes. The consequences of the infection include 
severe dehydration, cerebral edema, hypovolemic shock, renal failure and even death (Bishop, 
2009).  
The oral introduction of oral live attenuated rotavirus vaccines has significantly reduced 
the incidence of the disease, especially in developed countries (Payne et al., 2013). Despite 
this, However, due to financial and logistic problems these vaccines are scarcely used in 
lower income countries, leaving between a third to a half of children unprotected from severe 
rotavirus disease in countries with limited resources have left between a third to half of all 
vaccinated children unprotected (Babji & Kang, 2012). what highlights Thus, the need for 
alternative approaches to face the rotaviral gastroenteritis disease is of high priority. 
It is widely accepted that breastfeeding is the optimal way to provide infants with the 
essential nutrients for healthy growth and development, also protecting them against a broad 
spectrum of pathogens (Liu & Newburg, 2013; Peterson, Cheah, Grinyer, & Packer, 2013). 
When mothers cannot breastfeed their children, the nutrition recommended by the World 
Health Organization (WHO) can be delivered by is donated breast milk. This is a better 
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alternative than infant formula, at least for the first six months and especially for low-birth-
weight premature infants (Sousa, Delgadillo, & Saraiva, 2014b; WHO, 2003). In particular, 
the protein fraction of human milk plays an important role on its bioactivity (Lönnerdal, 
2016). Caseins and whey proteins represent approximately 40% and 60% of the total protein 
in human milk, the latter containing the majority of bioactive proteins like α-lactalbumin (α-
LA), lactoferrin (LF), immunoglobulins (Igs), human serum albumin, and lysozyme (Lyz). 
Milk fat globule membrane (MFGM) proteins, including mucins (MUCs), butyrophilin and 
lactadherin (LDH) represent less than 5% of human milk proteins (Peterson et al., 2013).  
One of the protection protective mechanisms attributed to human milk is associated to with 
glycoconjugates, mainly oligosaccharides and glycoproteins, whose glycan moieties may act 
as decoy receptors mimetics, hampering pathogen binding to the cell surface (Liu & Newburg, 
2013; Lönnerdal, 2016). While the protective activity of human milk oligosaccharides has 
been well established (Kunz, Kuntz, & Rudloff, 2014), human milk glycoproteins have 
received less attention, even though they seem to play important bioactive roles. At this 
respect, Although some studies have indicated the role of breastfeeding as a protective factor 
against rotavirus infection (De Franco et al., 2013; Gianino et al., 2002), there are few studies 
regarding the antirotaviral activity of the majority of human proteins. Most studies focus on 
those being mainly focused on IgA (Asensi, Martínez-Costa, & Buesa, 2006; De Franco et al., 
2013) or MFGM proteins MUC1 and LDH (Kvistgaard et al., 2004; Newburg et al., 1998; 
Yolken et al., 1992).  
In order to guarantee the hygienic quality of human milk, a pasteurization process at 62.5 
ºC for 30 min (holder pasteurization, HoP) is currently applied in human milk banks 
(Arslanoglu et al., 2010). Nevertheless, there are several studies reporting that thermal 
treatments usually applied to hygienization pasteurization of human milk might may lead to a 
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reduction of its beneficial and protective properties, affecting important biological 
components, such as proteins and in particular, immunoglobulins (Peila et al., 2017). 
Consequently, it would be advisable to develop treatments for human milk that can ensure 
microbial inactivation, while preserving its nutritional, immunological, and bioactive 
properties. At this respect, different alternative processing methods are currently being studied 
in order to evaluate their effect on human milk safety and quality, including Hhigh 
Ttemperature-Sshort Ttime (72-75 ºC, 15-20 s, HTST) pasteurization and Hhigh Hhydrostatic 
Ppressure (HHP) treatments. These treatments seem to maintain most organoleptic and 
nutritional properties of milk, causing minor degradation of proteins and vitamins than other 
treatments (Holsinger, Rajkowski, & Stabel, 1997). HHP treatment is a non-thermal 
processing method that can provide microbiologically safe, nutritionally intact, and products 
of high sensory quality of high-quality products by applying pressures in the range of 400-600 
MPa for 5-10 min (Sousa et al., 2014b). The pressure-induced sterilization and inactivation of 
non-enveloped and enveloped viruses, including rotaviruses, have been demonstrated in 
several studies (Pontes et al., 2001; Silva et al., 2014). 
Although there are several studies on the effect of technological treatments on the protein 
content of human milk (Peila et al., 2017), to our knowledge there are no studies focusing on 
its antirotaviral potential. The aim of the present study has been to prove was to evaluate the 
rotavirus-neutralizing activity of different human milk fractions and proteins, such as IgA, LF, 
Lyz, α-LA, MUCs, LDH and caseins, and to evaluate compare the effects of several heat and 
HHP pressure treatments on their antirotaviral activity. This activity has been was determined 
measuring the ability of milk fractions and proteins to inhibit the infection of MA104 cells by 
the WC3 bovine rotavirus strain. 
2. Materials and methods 
2.1. Cell culture and rotavirus propagation  
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Cell culture and rotavirus propagation have been performed following the procedures 
described in Parrón et al. (2016). The Rhesus monkey kidney cell line MA104 (ATTCC CRL-
2378) was used to propagate WC3 bovine rotavirus strain (ATCC VR-2102). Cells were 
cultured in minimum essential medium (MEM), supplemented with 10% heat-inactivated 
fetal bovine serum, 1% antibiotics (100 Units/mL penicillin, 100 µg/mL streptomycin), 2 mM 
L-glutamine, and 0.25 µg/mL amphotericin B. Rotavirus propagation was carried out by 
inoculating confluent cell monolayers with an aliquot of virus suspension. Serum-free MEM, 
supplemented with 1% antibiotics, 2 mM L-glutamine, and 0.25 µg/mL amphotericin B was 
used as diluent in all steps. All cell culture media and supplements were purchased from 
Gibco (Life Technologies Corporation, Paisley, UK). 
2.2. Obtaining human milk fractions: skimmed milk, whey, caseins and MFGM 
Transitional (6-15 days after birth) and mature (> 15 days after birth) human milk samples 
from ten healthy donors were kindly donated and stored at -20 ºC. The Ethical Committee for 
Clinical Research of the Government of Aragón (CEICA) approved the study and all donors 
provided informed consent. Frozen human milk was thawed and skimmed by centrifugation at 
2500 g for 15 min at 4 ºC. Whey was obtained from skimmed milk after precipitation of 
casein fraction as previously described (Svensson et al., 1999). In brief, human skimmed milk 
was supplemented with 10% (w/v) potassium oxalate and incubated at 4 ºC overnight. After 
lowering the pH to 4.3, heating to 32 ºC for 2 h, and incubating at 4 ºC overnight, the casein 
fraction was precipitated by centrifugation at 5000 g for 15 min at 20 ºC. The casein fraction 
was then washed three times with distilled water and dialyzed against phosphate-buffered 
saline (PBS) consisting of 0.14 M NaCl, 2.6 mM KCl, 8.1 mM Na2HPO4, 1.4 mM KH2PO4, 
pH 8.5. Human whey was filtered through glass wool and dialyzed against PBS pH 7.2. 
Human MFGM was isolated basically as described by Kvistgaard et al. (2004). Briefly, cream 
was obtained by centrifugation of human milk for 20 min at 5000 g, and washed twice with 
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10 mM Na2PO4, 0.15 M NaCl, pH 7.2. After intense churning and sonication of washed 
material, human MFGM was obtained by centrifugation at 50000 g for 1 h. All fractions were 
stored at -20 ºC until analysis. 
2.3. Purification of human proteins  
Human immunoglobulins A (IgA) were isolated by means of conventional fractionation 
using size-exclusion chromatography, according to Pack (2000). Thus, human Igs 
immunoglobulins were pelleted from whey by adding ammonium sulfate to 50% (w/v), 
followed by incubation for 16 h at 4 ºC and centrifugation at 15000 g for 1 h at 4 ºC. 
Afterwards, the pellet was dissolved and dialyzed against 0.02 M Tris-HCl buffer, pH 9.5, 
and further applied onto a DEAE-Sepharose column equilibrated with the same buffer. Bound 
IgA were eluted using the Tris buffer with a linear gradient from 0.10 to 0.25 M NaCl.  
Human lactoferrin (LF) was purified using cation exchange chromatography on SP-
Sepharose following the procedure of Conesa et al. (2008). In brief, milk was skimmed by 
centrifugation at 2500 g for 30 min at 4 ºC, diluted 1:1 with a buffer containing 0.04 M 
NaH2PO4, 0.8 M NaCl, 0.04% (v/v) Tween 20, pH 7.4, and batchwise incubated with SP-
Sepharose at 4 ºC overnight. Afterwards, the SP-Sepharose was packed onto a column and 
washed with a 0.02 M NaH2PO4 buffer, with 0.4 M NaCl, 0.02% (v/v) Tween 20, pH 7.4, to 
wash out the unbound proteins. LF was eluted with a buffer containing 0.02 M NaH2PO4, 1 M 
NaCl, pH 7.4. The iron saturation of LF, estimated from the ratio of absorbances at 280 and 
465 nm, was less than 15%. 
Three forms of recombinant human LF (rhLF) were also tested. Two forms were obtained 
from rice and kindly provided by Ventria Bioscience (Sacramento, CA, USA), in the holo 
form (~80% iron saturation) and as-isolated from rice (~60% iron saturation). Another rhLF 
from Aspergillus awamori (~18% iron saturation) was provided by Agennix (Houston, TX, 
USA). These proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel 
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electrophoresis (SDS-PAGE) showing a main band corresponding to a ~80 kDa protein, so 
they were used in the experiments without further purification. 
Human lysozyme (Lyz) was essentially obtained from human skimmed milk through 
cation exchange chromatography on SP-Sepharose, as described above for human LF 
purification, followed by gel-filtration on Sephadex G-50 of fractions excluded from SP-
Sepharose column. A recombinant human Lyz (rhLyz) obtained from rice was kindly supplied 
by Ventria Bioscience, and tested in this study after checking its purity, which was above 
95% as determined by SDS-PAGE (~14 kDa).  
Human α-lactalbumin (α-LA) was isolated according to Barbana et al. (2008). In short, 
human whey was obtained after skimming by centrifugation at 2000 g for 30 min at 4 ºC and 
further casein separation by adding CaCl2 and ultracentrifugation at 100000 g for 2 h at 4 ºC. 
Whey was then subjected to gel filtration chromatography on a Sephadex G-100 column 
equilibrated with 25 mM sodium acetate buffer, with 50 mM NaCl, pH 6.5, at 4 ºC, and 
further chromatographed under the same conditions on a Sephadex G-50 column.  
A fraction enriched in human mucins (MUCs) was obtained from human MFGM through 
an adapted method based on Le et al. (2012), including an initial step of enzymatic 
degradation by incubating first with pepsin (Sigma, St. Louis, MO, USA) at 0.4:100 (w/w) 
enzyme:protein ratio, for 2 h at 37 ºC with continuous shaking. Afterwards, the mixture was 
incubated with trypsin (Sigma) at 1:100 (w/w) enzyme:protein ratio, and α-chymotrypsin 
(Sigma) at 1:100 (w/w) enzyme:protein ratio, for 3.5 h at 37 ºC. Samples were then subjected 
to ultrafiltration through 30000 MWCO membranes, in order to remove small proteins and 
peptides.  
A fraction enriched in human lactadherin (LDH) was obtained by resuspension of MFGM 
with PBS containing 0.02 M NaCl and further centrifugation at 25000 g for 1 h at 4 ºC. The 
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resulting supernatant was enriched in LDH. All protein fractions were dialyzed against 
distilled water, lyophilized and stored at -20 ºC until analysis. 
2.4. Rotavirus infectivity assay  
The in vitro rotavirus infection assay was performed as previously described in the study of 
Parrón et al. (2016), in which the assay was validated according to international guidelines. 
Briefly, MA104 cells were seeded into 96-well plates and incubated near confluence. 
Appropriate dilutions of human milk fractions and proteins were mixed (1:1) with trypsin-
activated rotavirus suspension and incubated for 1 h at 37 ºC, to evaluate their neutralizing 
activity. Afterwards, the samples were transferred into the 96-well cell culture plates and 
incubated at 37 ºC during 1 h for rotavirus adsorption. Serum-free MEM and rotavirus 
suspension were included as negative and positive controls, respectively. For cell infection, 
plates were added with 100 µL per well of MEM containing 2 µg/mL of trypsin and 2% heat 
inactivated fetal serum, before incubating at 37 ºC in 5% CO2 for 16 h with gentle rotation. 
Virus-infected cells were detected afterwards by immunofluorescence. The infectivity 
percentages were determined by enumerating fluorescent foci (infected cells) in each well 
using a fluorescence microscope (Eclipse E400) with a FITC-compatible filter, by image 
analysis using the Zen lite 2012 software. 
2.5. Treatment of human fractions  
The protein concentrations of the samples selected for thermal and HHP treatments were 
those showing neutralization activity above 80%: pooled human whey at 2 mg protein/mL, 
IgA at 0.1 mg protein/mL, and LF at 2 mg protein/mL. The heat treatment procedure was 
based on that previously used (Parrón et al., 2016). The samples were placed in glass vials (~1 
mL) and heated in a thermostatic bath (± 0.1 ºC) at: 45 and 55 ºC for 60 min, 63 ºC for 30 min, 
72 ºC from 20 s to 60 min, and 75, 80 and 85 ºC for 20 s and 10 min. Temperature was 
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monitored inside the samples with a digital thermometer. After heating, the samples were 
cooled rapidly in an iced water bath and stored at -20 ºC until analysis. 
High pressure treatment procedure was based on that previously described by Mayayo et al. 
(2016). Aliquots of pooled human whey (2 mg protein/mL), IgA (0.1 mg protein/mL), and LF 
(2 mg protein/mL) were introduced into 2-mL polyethylene bags. After eliminating headspace, 
bags were heat-sealed and pressurised using a Stansted Fluid Power FPG 11500 B (Stansted, 
Essex, United Kingdom), with propylene glycol/water (70/30, v/v) as the pressure-
transmitting fluid. The chamber volume was of 30 mL. Pressure was raised to 400, 500 or 600 
MPa and maintained at those values for 5, 10 and 15 min. The pressure was increased at 240 
MPa/min, which gave come-up times of 1.6, 2.1 and 2.5 min at 400, 500 and 600 MPa, 
respectively. The initial temperature of transmitting fluid and samples was equilibrated at 20 
ºC, and the approximate temperature increase was 3 ºC per 100 MPa. HHP-treated samples 
were kept at 4 ºC until analysis. 
2.6. SDS-PAGE and Western-blotting 
Protein profiles of milk fractions and proteins were analyzed by SDS-PAGE using 4-20% 
polyacrylamide gels (Mini-Protean TGX, Bio-Rad Laboratories, Hercules, CA, USA), which 
were Coomassie and Periodic Acid Schiff (PAS) stained, according to standard procedures. 
Western-blotting procedure was performed to confirm the protein identity, in essence as 
described by Benfeldt et al. (1995) using PVDF membranes (Immobilon-P, Millipore 
Corporation, Bedford, MA, USA). Quantification of protein concentration was done by BCA 
Protein Assay (Pierce Kit, Thermo Scientific). The compositional values of human milk were 
obtained by infrared spectroscopy using a MilkoScan 4000 (Foss Electric, Hilleroed, 
Denmark). 
2.7. Statistical analysis 
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Data were analyzed for statistical significance with GraphPad Prism 5 software, by using a 
Kolmogorov-Smirnov normality test and a One-way ANOVA with Tukey's Multiple 
Comparison Test. 
3. Results and discussion 
3.1. Rotaviral neutralizing activity of human milk fractions and proteins 
It is widely accepted that the composition of human milk is influenced by many factors, 
such as genetics, lactation period, and dietary habits. These factors are responsible for the 
differences in human milk components between individuals, what makes difficult to establish 
a general composition (Sousa et al., 2014b; Wojcik, Rechtman, Lee, Montoya, & Medo, 
2009). The results we have found in the present study when evaluating the rotaviral activity of 
milks from different donors reflect that variability. In fact, even though there are not clear 
differences in the electrophoretic profile of human milk fractions from 10 healthy donors, 
significant differences have been evidenced when analyzing their neutralizing rotaviral 
activity (Fig. 1), obtaining values ranging from 3 to 100%, at 1 mg of protein/mL. Taking into 
account these wide differences between donors and in pursuit of achieving representative 
results, milk from the 10 donors was pooled. This pooled milk was the starting material for 
subsequent experiments to obtain fractions and proteins, which were subjected to 
compositional and biological assays. 
The electrophoretic profile of the samples tested in this study (Fig. 2) showed that the 
majority of the human milk proteins are whey proteins, the most abundant being α-LA, LF, 
IgA and Lyz, what is consistent with results from various studies, which indicate approximate 
contents of 17, 17, 11 and 5% of total human milk proteins, respectively (Peterson et al., 
2013). By contrast, both caseins and MFGM proteins, including MUCs and LDH, represent 
lower proportion compared to the whey fraction in human milk. Furthermore, the protein, 
lipid, and lactose percentages of human milk evaluated in this study are in good accordance 
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with compositional data reported by other authors (Sousa et al., 2014b). Thus, the pooled 
whole milk presented percentages of protein, lipid, and lactose of 1.1, 2.3 and 5.2% (w/v), 
respectively. 
It is widely accepted that breastfeeding acts as a protective factor against rotavirus 
infection (De Franco et al., 2013; Gianino et al., 2002). Despite the fact that human milk 
shows a complex composition, most of the studies performed on its antirotaviral capacity 
have mainly focused on IgA (Asensi et al., 2006; De Franco et al., 2013), or MFGM proteins 
MUC1 and LDH (Kvistgaard et al., 2004; Newburg et al., 1998; Yolken et al., 1992). Thus, 
there is a lack of studies addressing other human milk components, what underlines the need 
of new evidences to better understand their potential and action mechanisms against rotaviral 
infections. 
In the present study, several human milk fractions have been tested for their ability to 
reduce rotavirus infectivity (Fig. 3A). Thus, complete neutralization of in vitro cell infection 
with WC3 rotavirus was observed upon incubation either with raw whole milk, skimmed milk 
or whey, at 1 mg of protein/mL. By contrast, both casein and MFGM fractions showed 
significantly lower neutralizing values, being of 3 and 2%, respectively, at the same protein 
concentration, and higher values, of about 36 and 39% when tested at 2 mg of protein/mL. 
These results suggest that the antirotaviral potential of human milk is mainly associated to the 
whey fraction components. Moreover, the fat content appears not to be determinant in the 
overall activity, since no significant differences have been found between the antirotaviral 
activity of whole and skimmed human milk.  
Interestingly, significant interspecies differences in the antirotaviral activity have been 
found when analyzing the results of the human milk fractions in comparison with those 
obtained for their bovine counterparts in previous studies we performed under the same 
conditions (Parrón et al., 2016, 2017). In fact, we observed that bovine raw whole milk, 
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skimmed milk and whey, showed lower WC3 neutralizing values, being of 74, 73 and 93%, at 
1 mg of protein/mL, respectively. On the contrary, both bovine casein and MFGM fractions 
showed significantly higher antirotaviral activity, of 46 and 29% at the same protein 
concentration, respectively, than their human counterparts. Despite these divergences, the 
antirotaviral potential of bovine milk was found to be mainly associated with the whey 
fraction, as in the case of human milk. 
Results obtained with milk fractions are in good agreement with the rotavirus neutralizing 
activity shown by the isolated proteins assayed in this study (Fig. 3B). At this respect, both 
IgA and LF, the major human whey proteins, at a concentration of 1 mg/mL, reached 
neutralization values of 100 and 62%, respectively. However, α-LA and Lyz showed 
negligible activities, at 1 mg/mL and even at 2 mg/mL. Furthermore, it has been evidenced a 
certain degree of antirotaviral activity as regards both MUCs-enriched fraction (51%, at 1 
mg/mL) and LDH-enriched fraction (78%, at 0.5 mg/mL), which contrasted contrasts with the 
scarce activity previously attributed to MFGM whole fraction (2%, at 1 mg protein/mL). 
These MFGM proteins may easily act against rotavirus infection when totally solubilized in 
whey, better than as MFGM components. 
With respect to the antirotaviral activity exerted by the recombinant LF (rhLF) tested in 
this study, significant differences were observed in comparison with LF isolated from human 
milk. Thus, the three forms of rhLF assayed at 1 mg/mL showed neutralizing values of 95, 95 
and 87%, for the rice holo, the rice as isolated, and the Aspergillus awamori rhLF, 
respectively, which are statistically significant higher than that obtained with human milk LF 
(62% neutralizing activity). These results seem to indicate that there is no correlation between 
the degree of LF iron saturation and its antirotaviral activity, which is in agreement with 
results obtained by Superti et al. (2001) who found that complete iron saturation of bovine LF 
did not modify its antirotaviral activity. By contrast, no significant differences were found 
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between antirotaviral activity of Lyz from human milk and the recombinant protein obtained 
from rice. 
Our results are in good accordance with those obtained by Asensi et al. (2006) who 
demonstrated the neutralizing activity of human milk against three rotavirus strains (human 
Wa and VA70, simian SA11). These authors found no correlation between the antirotaviral 
activity and the concentrations of IgA in human milk and serum samples, suggesting that 
antirotavirus IgA were only partly responsible for this activity and pointing out that other 
bioactive components, such as LF and LDH, could also be involved. Similar results were also 
reported by De Franco et al. (2013) as they observed that human colostrum and milk samples 
had the capacity to neutralize the rotavirus independently of their anti-rotaviral IgA levels , 
indicating a potential protective role of other components besides Igs immunoglobulins. 
Furthermore, interspecies differences have been reported on the antirotaviral potential of milk 
IgA. Thus, it has been shown that bovine milk predominant Igs immunoglobulins (IgG) 
presented a higher activity over 90% at 0.025 mg/mL (Parrón et al., 2016) than those 
predominant in human milk (IgA), around 55% at 0.025 mg/mL. These differences could be 
attributed to the vaccination programmes commonly applied in bovine species, resulting in 
milk with a high titer of specific antirotavirus Igs immunoglobulins. 
As regards the antirotaviral capacity of human LF, our results have shown that its 
neutralizing activity against WC3 strain is close to 40% at a concentration of 0.25 mg/mL. 
This finding contrasts contrasted with that we obtained previously, which showed that native 
bovine LF at the same concentration could inhibit about 82% of WC3 rotavirus infection of 
MA104 cells (Parrón et al., 2016). These results were very similar to those obtained by 
Superti et al. (2001) who showed that apo and holo forms of bovine LF at 0.2 mg/mL exerted 
an inhibition of SA-11 strain, from 75 to 85%, in human colon adenocarcinoma cells (HT-29). 
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With reference to human MUCs, our results showed a WC3 rotavirus-neutralizing activity 
of 34% at 0.25 mg/mL. In this regard, Yolken et al. (1992) have also attributed antirotaviral 
activity to a human milk mucin complex fraction containing the MFGM protein MUC1 at 0.1 
µg/mL, which showed 50% of inhibition of MA104 cell infection with SA11 rotavirus strain. 
Furthermore, we have previously demonstrated that infection of MA104 cells by WC3 
rotavirus strain was 35% inhibited by bovine MUC1 at 0.25 mg/mL (Parrón et al., 2016). 
However, no inhibitory effect was observed by Kvistgaard et al. (2004) with a similar fraction, 
on infection by rotavirus strain Wa, suggesting the great influence of the strain when studying 
their inhibitory factors. 
The present study has proved showed that human LDH at a concentration of 0.1 mg/mL 
has a WC3 neutralizing activity of 40%. In this respect, Kvistgaard et al. (2004) reported that 
human LDH inhibited infection of Caco-2 cells by rotavirus strain Wa in a dose-dependent 
manner (60% inhibition at 0.1 mg/mL). Likewise, Yolken et al. (1992) also suggested that 
human LDH was able to block the entry of rotavirus into the host cell, activity that was 
mainly attributed to the presence of sialic acid glycan chains in LDH. Furthermore, Newburg 
et al. (1998) evaluated the correlation between the concentration of LDH in breast milk and 
the appearance of symptomatic rotavirus infection. The results obtained showed the existence 
of significant differences between LDH concentration in milk received by symptomatic (29.2 
μg/mL) and asymptomatic (48.4 μg/mL) infected babies. In addition, Parrón et al. (2016) 
observed that the incubation of WC3 rotavirus with bovine LDH at 0.08 mg/mL resulted in a 
neutralizing activity of 70%. In contrast, Kvistgaard et al. (2004) observed that bovine LDH 
could not inhibit Wa rotavirus infection of Caco-2 cells, revealing again the differences that 
may exist in the sensitivity of strains to inhibitory factors. 
Differences in the neutralizing activity exhibited by milk fractions or proteins assayed in 
several studies could be attributed to either inter or intraspecies divergences in their overall 
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composition and structure. In particular, differences in the glycosylation degree and 
microheterogeneity of the attached glycans to proteins should be considered, as several 
studies pointed out that glycosylation is involved in receptor-ligand and host-pathogen 
interactions (Liu & Newburg, 2013; Peterson et al., 2013). This could explain the different 
activities observed in the present study between glycosylated (IgA, LF, MUCs and LDH) and 
poorly or non-glycosylated proteins (α-LA and Lyz). In addition, it is necessary to take into 
account the differences between the rotavirus strains used, with regard to their binding 
preferences to glycans, particularly sialic acid (Arias et al., 2016; Prasad et al., 2014). 
Furthermore, some discrepancies could derive from differences between the neutralization 
protocols, protein purification procedures, cell lines, inoculation time and methods to detect 
infection used. 
3.2. Effect of heat treatment on the antirotaviral activity of human milk fractions and proteins 
The effect of heat treatments of different intensity applied to human whey on its inhibitory 
activity against WC3 rotavirus was determined (Fig. 4A). It was observed that HoP (63 ºC for 
30 min), caused a significant decrease of the neutralizing activity of human whey, of 
approximately 30%, whereas HTST pasteurization treatments (72 ºC for 20 s and 75 ºC for 20 
s) did not affect its antirotaviral capacity. These results highlight the fact that these last 
treatments could be used as alternative methods for processing human milk to preserve its 
bioactivity. Heat treatments of high intensity, between 72 ºC for 10 min and 85 ºC for 10 min, 
induced higher losses of activity, of 40 and 98%, respectively. The electrophoretic profile of 
human whey samples subjected to severe heat treatments (Fig. 4B) showed the presence of 
aggregates that could not enter the wells and a slight decrease in the intensity of some protein 
bands. 
Taking into account that IgA and LF are the proteins that have mainly shown antirotaviral 
activity in human whey, we also evaluated the effect of different heat treatments on their 
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activity (Fig. 5A). HoP affected significantly to both proteins, causing a decrease of the 
neutralizing activity, of 98 and 60%, for IgA and LF, respectively. By contrast, HTST 
pasteurization, at 75 ºC for 20 s, did not affect the antirotaviral activity of IgA and LF. 
However, heat treatments of higher intensity (75 ºC for 10 min and 85 ºC for 10 min) caused 
significant losses of LF and IgA activity, between 82 and 100%. The decrease in the intensity 
of the electrophoretic bands corresponding to IgA and LF after heat treatments was in 
accordance with the neutralizing results (Fig. 5B). 
Most of the studies performed to determine the effect of technological treatments on 
human whey proteins have been focused on defensive components, such as IgA, LF and Lyz 
(Peila et al., 2017), while none of them has focused on their antirotaviral activity. Thus, 
Mayayo et al. (2016) observed that HoP and HTST pasteurization of human milk caused a 
decrease of about 57% of IgA immunoreactivity measured by enzyme-linked immunosorbent 
assay (ELISA), whereas thermal treatments of higher intensity (over 80 ºC for 15 s) produced 
losses higher than 78%. Although diverse studies have reported similar IgA losses after HoP 
pasteurization, ranging between 49 and 60% (Contador, Delgado-Adámez, Delgado, Cava, & 
Ramírez, 2013; Giribaldi et al., 2016; Viazis, Farkas, & Allen, 2007), other studies have 
evidenced lower losses, ranging from 20 to 28% (Chang et al., 2013; Czank, Prime, Hartmann, 
Simmer, & Hartmann, 2009; Permanyer et al., 2010; Sousa, Delgadillo, & Saraiva, 2014a), or 
even no degradation of IgA (Evans, Ryley, Neale, Dodge, & Lewarne, 1978). Furthermore, 
Giribaldi et al. (2016) showed that HTST pasteurization preserved 79% of IgA 
immunoreactivity, while HoP pasteurization only preserved 46%; in contrast to other authors 
that showed similar losses of IgA after applying HoP or HTST treatments (Mayayo et al., 
2016; Peila et al., 2017). 
Human LF has also been reported to be altered after thermal treatments. Several studies 
agreed that HoP pasteurization of human milk causes a decrease of LF immunoreactivity, 
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with losses ranging from 57 to 80% (Chang et al., 2013; Mayayo et al., 2014; Peila et al., 
2016). Furthermore, several authors have pointed out that even HTST pasteurization may 
affect LF immunoreactivity, while to a lesser extent than HoP, causing losses from 35-60% 
(Mayayo et al., 2014; Peila et al., 2016). Heat treatments at lower temperatures, such as 40 ºC 
or 60 ºC for 30 min, did not cause significant changes in LF and IgA immunoreactivity 
(Chang et al., 2013). 
At this respect, the present study points out that HTST pasteurization treatment preserves 
the antirotaviral activity of human whey, IgA and LF, better than HoP, what should be taken 
into account in the design of human milk processing conditions in order to maintain its 
bioactivity.  
3.3. Effect of HHP treatment on the antirotaviral activity of human milk fractions and 
proteins 
HHP treatments of different intensity were applied to human whey in order to evaluate the 
effect on its rotaviral neutralizing activity (Fig. 6A). HHP treatments were slightly harmful to 
the antirotaviral activity of samples. In fact, HHP treatments at 400 and 500 MPa, for 5, 10 
and 15 min, did not affect significantly the activity of human whey, as previously observed 
for HTST pasteurization. Likewise, the more severe HHP treatments of whey at 600 MPa for 
5, 10 and 15 min, led to slight decreases of neutralizing activity, of 6, 6 and 9%, respectively, 
which is much lower than that produced by HoP (30%). The electrophoretic profile of HHP 
treated human whey (Fig. 6B) was in good accordance with the neutralizing results, since no 
apparent changes were observed in the intensity of the electrophoretic bands. 
The effect of different HHP treatments on the rotavirus-neutralizing activity of native IgA 
and LF was different (Fig. 7A). It has been shown evidenced that HHP treatment seems to be 
more harmful to IgA than to LF. Thus, HHP treatments at 400, 500 and 600 MPa for 15 min 
caused significantly losses of the antirotaviral activity of IgA, of 21, 30 and 40%, respectively. 
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These losses were much lower than those produced after HoP (98%), and significantly higher 
than those obtained after HTST pasteurization (0% of loss). However, none of the HHP 
treatments tested on LF, 400, 500 and 600 MPa for 15 min, affected significantly its activity, 
similarly to results obtained after HTST pasteurization, while in contrast with the 60% loss 
produced after HoP. Furthermore, no decrease in the intensity of the electrophoretic bands 
corresponding to human IgA and LF after HHP treatments was observed (Fig. 7B), what may 
correlate with a minor damage of samples, in accordance with the neutralizing results. 
Several studies have been carried out on the effect of applying HHP treatment to human 
milk, specifically determining IgA and LF content and immunoreactivity. Even though HHP 
has been reported to be less harmful to proteins than HoP, as we have observed in our study, 
some divergences exist among results from different studies. Thus, Sousa et al. (2014a) found 
that immunoreactivity of IgA was fully preserved after HHP treatment of human colostrum at 
200 and 400 MPa up to 30 min, and even after pressures up to 600 MPa for 2.5 min. By 
contrast, in the same study it was shown that HHP treatment at 600 MPa for 15 min led to 
similar IgA losses than HoP pasteurization (20%). Furthermore, Viazis et al. (2007) showed 
that HHP processing of human milk at 400 MPa for 30, 60, 90, and 120 min resulted in losses 
of 14, 13, 19 and 25% IgA immunoreactivity, respectively, being lower than the decrease 
produced after HoP pasteurization (49%). Other studies have also indicated a high 
maintenance of IgA after HHP treatment of human milk. Thus, no loss of IgA was observed 
after treatment at 400 MPa for 5 min, while losses of 12 and 31% were produced after 500 
and 600 MPa for 5 min, respectively (Permanyer et al., 2010). Contador et al. (2013) showed 
that human milk treated at 400 MPa for 6 min maintained IgA levels, determined by ELISA, 
higher than those resulting after HoP; whereas at 600 MPa for 6 min the decrease was similar 
to that obtained after HoP (50-60%). Similar results were observed by Mayayo et al. (2016) 
who showed that HHP treatments at 300, 400, 500 and 600 MPa for 30 min led to a decrease 
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of IgA concentration of 20, 42, 53 and 64%, respectively, whereas HoP pasteurization caused 
a decrease of approximately 57%. 
The effect of HHP on LF denaturation has been also investigated. HHP treatment of human 
milk at pressures of 300, 400, 500 and 600 MPa for 15 min resulted in 9, 23, 34 and 48% of 
LF denaturation, respectively, whereas HoP pasteurization denatured 80% (Mayayo et al., 
2014). The same study also pointed out that LF aggregation did not take place after HHP, 
whereas aggregates involving disulphide bonds occurred during thermal treatments. 
Divergences in results obtained between studies could be mainly attributed to different 
treatment conditions and equipment, with particular focus on holding times and initial 
temperature of the samples, and transmitting fluid in the pressure chamber. In fact, it is known 
that temperature reached during pressure treatment due to adiabatic compression is an 
important parameter that influences protein denaturation, as it has been observed for IgA 
(Delgado et al., 2013). 
Results derived from the present study clearly suggest that HHP treatment, at pressures 
<600 MPa for 15 min, is a potential alternative to HoP pasteurization of human milk, in terms 
of antirotaviral activity retention. However, more studies are needed to elucidate whether 
these conditions for treatment also respect the overall nutritional and hygienic quality criteria 
demanded by human milk banks. 
4. Conclusions 
The results obtained in this study demonstrated that human milk is a valuable source of 
antirotaviral compounds, with whey fraction and the proteins IgA and LF showing the higher 
capacity. HoP pasteurization, which is currently recommended in all international human milk 
bank guidelines, has been proved to significantly decrease the antirotaviral activity of human 
whey, IgA and LF. Both HTST pasteurization and HHP treatment, at pressures <600 MPa, 
have shown promising results as potential alternatives to HoP pasteurization of human milk, 
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in terms of retention of antirotaviral activity. Despite that, more research is necessary in order 
to know which technological treatments and conditions should be applied to human milk to 
ensure microbiological safety, as well as maintenance of biological activity, making those 
treatments a reliable alternative to the conventional HoP pasteurization. 
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Figure captions  
Fig. 1. (A) Effect of human milk fractions from ten donors (numbered 1-10) on 
neutralizing WC3 rotaviral infection of MA104 cells. ( ) Whole milk at 1 mg protein/mL; 
( ) skimmed milk at 1 mg protein/mL; ( ) whey at 0.5 mg protein/mL; ( ) casein fraction 
at 4 mg protein/mL. Results are shown as mean ± standard deviation of triplicates from two 
independent experiments (n=6). (B) Electrophoretic profile of skimmed human milk from ten 
donors (numbered 1-10). SDS-PAGE was performed under reducing conditions in 4-20% 
polyacrylamide gradient gel. PAS + Coomassie staining. LF, lactoferrin; IgA, 
immunoglobulins A; α-LA, α-lactalbumin; Lyz, lysozyme; M, molecular weight marker. 
 
Fig. 2. Electrophoretic profile of human fractions and proteins. Lane 1, whole milk; lane 2, 
skimmed milk; lane 3, whey; lane 4, casein fraction; lane 5, MFGM fraction; lane 6, 
immunoglobulins A (IgA); lane 7, lactoferrin (LF); lane 8, lysozyme (Lyz); lane 9, α-
lactalbumin (α-LA); lane 10, mucins enriched fraction (MUCs); lane 11, lactadherin enriched 
fraction (LDH); M, molecular weight marker. SDS-PAGE was performed under non-reducing 
conditions in 4-20% polyacrylamide gradient gel. PAS + Coomassie staining.  
 
Fig. 3. Dose-response of human samples on neutralizing WC3 rotaviral strain infectivity of 
MA104 cells. (A) Human milk pooled fractions: (○) whole milk; (●) skimmed milk; (□) whey; 
(■) casein fraction; (∆) MFGM defatted fraction. (B) Human milk proteins: (○) 
immunoglobulins A; (●) lactoferrin; (□) lysozyme; (■) α-lactalbumin; (∆) mucins enriched 
fraction; (▲) lactadherin enriched fraction. Results are shown as mean ± standard deviation 
of triplicates from two independent experiments (n=6). 
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Fig. 4. Effect of heat treatment on the neutralizing activity of human whey against WC3 
rotaviral strain infection of MA104 cells. (A) Results are expressed in relation to control (non-
treated whey) as mean ± standard deviation of triplicates from two independent experiments 
(n=6). Asterisks indicate statistically significant differences (***p < 0.001) in relation to 
control. Whey was treated at 2 mg/mL protein concentration. (B) Electrophoretic profile of 
heat treated human whey. SDS-PAGE was performed under non-reducing conditions in 4-
20% polyacrylamide gradient gel. PAS + Coomassie staining. LF, lactoferrin; IgA, 
immunoglobulins A; M, molecular weight marker. The code number corresponds to the 
numbers in brackets as regards thermal treatments. 
 
Fig. 5. Effect of heat treatment on the neutralizing activity of human immunoglobulins A ( ) 
and lactoferrin ( ) against WC3 rotaviral strain infection of MA104 cells. (A) Dose-
response results expressed in relation to control (non-treated proteins) as mean ± standard 
deviation of triplicates from two independent experiments (n=6). Asterisks indicate 
statistically significant differences (***p < 0.001; **p < 0.01) in relation to control. 
Immunoglobulins A (IgA) and lactoferrin (LF) were treated at 0.1 and 2 mg/mL, respectively. 
(B) Electrophoretic profile of heat treated human proteins. SDS-PAGE was performed under 
non-reducing conditions in 4-20% polyacrylamide gradient gel. Coomassie staining. The code 
number corresponds to the numbers in brackets as regards thermal treatments. 
 
Fig. 6. Effect of HHP treatment on the neutralizing activity of human whey against WC3 
rotaviral strain infection of MA104 cells. (A) Results expressed in relation to control (non-
treated whey) as mean ± standard deviation of triplicates from two experiments (n=6). 
Asterisks indicate statistically significant differences (***p < 0.001) in relation to controls. 
Whey was treated at 2 mg/mL of protein concentration. (B) Electrophoretic profile of HHP 
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treated human whey. SDS-PAGE was performed under non-reducing conditions in 4-20% 
polyacrylamide gradient gel. PAS + Coomassie staining. LF, lactoferrin; IgA, 
immunoglobulins A; M, molecular weight marker. The code number corresponds to the 
numbers in brackets as regards HHP treatments. 
 
Fig. 7. Effect of HHP treatment on the neutralizing activity of human immunoglobulins A ( ) 
and lactoferrin ( ) against WC3 rotaviral strain infection of MA104 cells. (A) Results 
expressed in relation to control (non-treated proteins) as mean ± standard deviation of 
triplicates from two experiments (n=6). Asterisks indicate statistically significant differences 
(***p < 0.001) in relation to controls. Immunoglobulins A (IgA) and lactoferrin (LF) were 
treated at 0.1 and 2 mg/mL, respectively. (B) Electrophoretic profile of HHP treated human 
proteins. SDS-PAGE was performed under non-reducing conditions in 4-20% polyacrylamide 
gradient gel. Coomassie staining. The code number corresponds to the numbers in brackets as 
regards HHP treatments. 
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Highlights 
 The antirotaviral activity of several human milk fractions and proteins was 
proved. 
 Human whey fraction, at 1 mg protein/mL, showed 100% rotavirus 
neutralization. 
 HoP significantly decreased the antirotaviral activity of human whey, IgA and 
LF.  
 The percentage of decrease upon HoP ranged 30-98% for human whey, IgA 
and LF. 
 HTST and HHP are promising alternatives to HoP for human milk treatment. 
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